دورية أكاديمية
[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
| العنوان: | [Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia]. |
|---|---|
| المؤلفون: | Chen XM; Second Clinical College, Southern Medical University, Guangzhou 510515, Guangdong Province, China.; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Weng JY; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China. E-mail: wengjianyu1969@163.com., Deng CX; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Wang YL; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Chao Z; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Lai PL; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Li MM; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Liao PJ; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Huang X; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Ling W; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Wan CC; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Wu SJ; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Zhong LY; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Lu ZS; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., Zou XL; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China., DU X; Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China. |
| المصدر: | Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2016 Apr; Vol. 24 (2), pp. 399-404. |
| نوع المنشور: | Journal Article |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN: 1009-2137 (Print) Linking ISSN: 10092137 NLM ISO Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za Zhi Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Beijing : Zhongguo shi yan xue za zhi she, |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy, Adolescent ; Adult ; Agranulocytosis ; Cladribine/therapeutic use ; Cytarabine/therapeutic use ; Female ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Male ; Middle Aged ; Remission Induction ; Thrombocytopenia ; Topotecan/therapeutic use ; Young Adult |
| مستخلص: | Objective: To explore the clinical efficacy and toxicity of CLAT protocol (cladribine, cytarabine and topotecan) for treating patients with refractory acute myeloid leukemia (R-AML). Methods: A total of 18 patients with R-AML (median age 37 years, range 18 to 58 years; male n = 16, female n = 2) were treated with CLAT protocol, which consisted of cladribine 5 mg/m(2)/d, i.v. on days 1-5, cytarabine 1.5 g/m(2)/d, i.v. on days 1-5, topotecan 1.25 mg/m(2)/d, i.v. on days 1-5 and G-CSF 300 µg/d subcutaneous injection on day 6 until neutrophile granulocyte recovery. Results: Out of 18 patients 2 died of severe infection before the assessment. Among 16 evaluated patients, 10 (55.6%) achieved complete remission (CR), and 2 (11.1%) achieved partial remission (PR), the overall response rate was 66.7%, the rest 4 patients did not respond (NR). The median overall survival time and DFS for the CR patients was 9.5 months (95%CI: 6.7-16.64) and 9.5 months (95%CI: 6.1-16.7) respectively. The 1 year OS and DFS rates were 45% and 46.9%, respectively. All patients developed grade 4 of granulocytopenia and thrombocytopenia, the median duration was 13 (range 2 to 21) days and 12 days (range 2 to 21), respectively, all patients developed infection, 2 patients died of severe infection. The most common non-hematological side effects included nausea, vomiting, diarrhoea, rash, aminotransferase or bilirubin elevation and were grade 1 to 2. Conclusion: The CLAT protocol seems to have promising for the treatment of refractory AML patients, and patients well tolerated. This CLAT protocol offers an alternative treatment for R-AML patients who received severe intensive treatment, especially with anthracycline-containing chemotherapy. |
| المشرفين على المادة: | 04079A1RDZ (Cytarabine) 143011-72-7 (Granulocyte Colony-Stimulating Factor) 47M74X9YT5 (Cladribine) 7M7YKX2N15 (Topotecan) |
| تواريخ الأحداث: | Date Created: 20160507 Date Completed: 20160915 Latest Revision: 20181202 |
| رمز التحديث: | 20231215 |
| DOI: | 10.7534/j.issn.1009-2137.2016.02.017 |
| PMID: | 27150999 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1009-2137 |
|---|---|
| DOI: | 10.7534/j.issn.1009-2137.2016.02.017 |